Arthrosamid is a polyacrylamide hydrogel developed by Contura International Ltd. as a long-lasting intra-articular injection approved in Europe for the treatment of knee osteoarthritis (OA). The treatment has the potential to change the present care pathway for managing osteoarthritis, which affects around one in four adults in Ireland aged over 601 (over 400,000 people)2 and current treatments are not long lasting or involve invasive knee replacement surgery. Despite a large suffering population, there has been very little innovation in the range of osteoarthritis treatments on offer to meaningfully help patients – until now.

Navigating Arthrosamid Access in the UK: NHS Eligibility, Private Insurance Coverage, and Self-Funding Options
Discover how to access Arthrosamid treatment for knee osteoarthritis in the UK. This innovative polyacrylamide hydrogel injection offers pain relief and improved joint mobility. While Arthrosamid is licensed in the UK, it is not yet widely available through the NHS, pending further evidence and evaluations by NICE. Private health insurance coverage varies and typically requires specialist referrals and pre-approval. Self-funding options, payment plans, and patient access programs offer alternative routes. Stay informed by consulting healthcare providers and insurers to make the best choice for your treatment journey.
